BCI Pharma is delighted to announce preclinical studies confirmed the broad therapeutic potential of its CSF1R inhibitors. These meaningful and compelling preclinical data come from a fruitful partnership with Mithra Women’s Health and cover medical areas for which unsatisfied therapeutic needs persist including cancer, endometriosis and inflammatory disorders.

Follow the link to read Mithra’s press release.